x

Search for a clinical trial

* (*) mandatory field

A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy -GB

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Ongoing trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Eli lilly and company world headquarters
  • Website
    • Phase : I
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - US
  • ADDRESS: NOT PROVIDED - US
  • UNITED STATES
  • More information
  • Phone  : -
  • Fax  : -
Last update: May 2019

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.